Here's what we'll cover
Here's what we'll cover
If a weekly injection has been the one thing keeping you from trying a GLP-1 medication, you are not alone. That is a big reason the Wegovy pill has grown so quickly since it launched in the United States in early January 2026.
Here is what the prescription data shows, how the pill compares with the injection, and what to weigh before you ask for it.
What Is the Wegovy Pill?
The Wegovy pill is oral semaglutide, the same active ingredient as Wegovy injection and Ozempic. According to the Wegovy prescribing information, Wegovy tablets are FDA approved for adults to reduce excess body weight and maintain weight reduction long term, and to reduce the risk of major cardiovascular events in adults with established heart disease and obesity or overweight.
Treatment starts at 1.5 mg once daily and is increased every 30 days to the 25 mg maintenance dose. Unlike Wegovy injection, which is also approved for adolescents 12 and older, the tablets are approved for adults only.
The pill uses an absorption enhancer called SNAC that helps semaglutide pass through the stomach lining before it breaks down. That is why the dosing rules are strict.
What the Prescription Data Shows
- In its first full week after launch, the Wegovy pill tracked 18,410 U.S. prescriptions, according to IQVIA data reported by BNN Bloomberg, a start analysts said was ahead of other GLP-1 launches.
- By August 2026, it was tracking roughly 172,000 weekly prescriptions, according to IQVIA figures cited by Citi and reported by HLTH.
- Over the same period, Eli Lilly's rival pill Foundayo (orforglipron) was growing from a smaller base, at about 34,000 weekly prescriptions.
- These figures may not fully capture telehealth prescriptions, so actual use may be higher.
Growth likely reflects needle avoidance, low starting self pay prices, and broader prescribing by primary care and telehealth providers. More prescriptions do not mean the pill works better than the injection. They mean more people are choosing it.
How the Pill Compares on Weight Loss
In the OASIS 4 trial, published in the New England Journal of Medicine, oral semaglutide 25 mg produced an average weight loss of 13.6% at 64 weeks, compared with 2.2% on placebo. For comparison, injectable semaglutide 2.4 mg produced about 15% average weight loss in the STEP 1 trial, and tirzepatide reached up to about 21% in SURMOUNT 1.
So the pill lands close to the standard Wegovy injection, though trials were run separately and are not direct comparisons. Gastrointestinal side effects were common, reported by 74% of people on the pill versus 42% on placebo in OASIS 4.
| Factor | Wegovy injection | Wegovy pill | Foundayo pill |
|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Orforglipron |
| Dosing | Once weekly injection | Once daily tablet | Once daily tablet |
| Food rules | Any time, with or without meals | Empty stomach, up to 4 oz water, wait 30 minutes | With or without food |
| Average weight loss in key trial | About 15% at 68 weeks (2.4 mg) | 13.6% at 64 weeks (25 mg) | About 11% at 72 weeks (highest dose) |
| Approved ages | Adults and adolescents 12 and older | Adults | Adults |
The Strict Dosing Rules
Per the label, these steps matter for absorption:
- Take the tablet first thing in the morning on an empty stomach.
- Swallow it whole with no more than 4 ounces of plain water, and no other liquids.
- Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications.
- Do not split, crush, or chew the tablet.
If your mornings start with coffee, other pills, or breakfast right away, you will need to adjust your routine. Some patients find this easy. Others find a weekly injection simpler in practice.
Foundayo: The Other GLP-1 Pill
The FDA approved Eli Lilly's Foundayo on April 1, 2026, according to BioSpace. It is a small molecule GLP-1 pill that, per its prescribing information, can be taken once daily with or without food. In its trials, the highest dose produced about 11% average weight loss at 72 weeks versus about 2% on placebo. Its main advantage is flexibility rather than larger weight loss.
What the Pill Costs
The pill's low starting price is a major reason for its growth. As of October 2026, manufacturer self pay prices compiled by Kymata Health were:
| Medication | Typical self pay monthly price |
|---|---|
| Wegovy pill | $149 (1.5 mg), $199 (4 mg), $299 (9 mg or 25 mg) |
| Foundayo | $149 to start, about $299 at maintenance |
| Wegovy pen | $199 for starter doses, $349 for 1 to 2.4 mg, $399 for 7.2 mg |
| Zepbound | $299 to $449 by dose |
With commercial coverage, savings cards may lower costs further, and eligible Medicare Part D enrollees can get Wegovy, Zepbound, or Foundayo for $50 a month through the Medicare GLP-1 Bridge through 2027. Check GLP-1 coupons and savings programs for current offers, since prices change often.
Questions to Ask Your Provider
- Is the pill or the injection a better fit for my health history and goals?
- Can I reliably follow the empty stomach morning routine every day?
- Do any of my morning medications conflict with the 30 minute wait?
- Does my insurance cover the pill, or is self pay cheaper for me?
- Would Foundayo's flexible dosing or Zepbound's larger average weight loss suit me better?
No waiting list. No insurance needed.
Frequently Asked Questions
Is the Wegovy pill FDA approved for weight loss?
Yes. Wegovy tablets are FDA approved for adults to reduce excess body weight and maintain weight loss long term, and to reduce cardiovascular risk in adults with established heart disease and obesity or overweight.
How much weight do people lose on the Wegovy pill?
In the OASIS 4 trial, oral semaglutide 25 mg produced 13.6% average weight loss at 64 weeks, compared with 2.2% on placebo.
How do you take the Wegovy pill?
Take it once daily in the morning on an empty stomach with up to 4 ounces of plain water, swallow it whole, and wait at least 30 minutes before eating, drinking, or taking other oral medicines.
How much does the Wegovy pill cost without insurance?
As of October 2026, manufacturer self pay prices were about $149 for 1.5 mg, $199 for 4 mg, and $299 for the 9 mg and 25 mg doses.
How many people are taking the Wegovy pill?
IQVIA data cited by Citi showed roughly 172,000 weekly U.S. prescriptions by August 2026, up from 18,410 in its first full week after launch.
What is the difference between the Wegovy pill and Foundayo?
The Wegovy pill is oral semaglutide and must be taken on an empty stomach. Foundayo is orforglipron, a different GLP-1 pill that can be taken with or without food. Their trial results differ.
The Bottom Line
The Wegovy pill has grown from about 18,000 prescriptions in its first full week to roughly 172,000 a week by August 2026, making it the leading GLP-1 pill in the United States. In its main trial it produced 13.6% average weight loss, close to the standard Wegovy injection, with self pay prices starting at $149 a month.
It is not automatically the right choice. The daily empty stomach routine is strict, and some patients will do better with a weekly injection or with Foundayo's flexible dosing. The best GLP-1 is the one you can take consistently, afford, and tolerate. To find a prescriber who offers both pills and injections, compare vetted telehealth providers. Always consult your physician before starting, switching, or stopping any medication.